15 results on '"Shibata, Yuhei"'
Search Results
2. Evaluation of the effectiveness of caspofungin against febrile neutropenia and the factors related to the alteration in its plasma concentration.
- Author
-
Shibata, Yuhei, Miyahara, Yuri, Sadaka, Yuna, Yasue, Mika, Fujimura, Minami, Soda, Midori, Yamamoto, Miho, Kato, Hiroko, Suzuki, Akio, Tsukamoto, Katsura, Hara, Takeshi, Tsurumi, Hisashi, and Kitaichi, Kiyoyuki
- Subjects
- *
FEBRILE neutropenia , *ANTIFUNGAL agents , *NEPHROTOXICOLOGY , *HEPATOTOXICOLOGY , *BODY weight , *ECHINOCANDINS - Abstract
Caspofungin (CPFG) is an echinocandin antifungal agent that inhibits the synthesis of β-1, 3-D-glucan, a critical component of the cell wall of target fungi. Several clinical studies have confirmed the efficacy and safety of CPFG in patients with febrile neutropenia (FN); however, there are no reports available in Japanese patients with FN. Therefore, we investigated the therapeutic efficacy and pharmacokinetics of CPFG as an empirical therapy in a Japanese hospital. Twenty-four Japanese patients, who were diagnosed with FN at Gifu University Hospital from February 2014 to August 2017, were enrolled. Blood samples were collected at the end of CPFG dosing (0.5 h after the infusion) on day 1 and immediately prior to the next infusion on days 2, 3, and 4. The concentration of CPFG in plasma was measured by high-performance liquid chromatography. The efficacy was assessed by five of the component endpoints, and safety was monitored according to the Common Terminology Criteria for Adverse Events. CPFG showed an excellent effect against FN (75%, 18/24), without any serious hepatic or renal toxicity. Regarding the pharmacokinetics, the plasma concentration of CPFG was significantly correlated with body weight; although, no correlation was observed between the plasma concentration of CPFG and the other factors investigated, such as gender or laboratory results. These results suggest the high efficacy, safety, and tolerability of CPFG as an empirical antifungal therapy for Japanese patients with FN. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
- Author
-
Shibata, Yuhei, Hara, Takeshi, Nagano, Junji, Nakamura, Nobuhiko, Ohno, Tomohiko, Ninomiya, Soranobu, Ito, Hiroyasu, Tanaka, Takuji, Saito, Kuniaki, Seishima, Mitsuru, Shimizu, Masahito, Moriwaki, Hisataka, and Tsurumi, Hisashi
- Subjects
- *
LIVER cancer , *INDOLEAMINE 2,3-dioxygenase , *NITROSOAMINES , *CARCINOGENESIS , *ENDOENZYMES - Abstract
Indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing intracellular enzyme of the L-kynurenine pathway, causes preneoplastic cells and tumor cells to escape the immune system by inducing immune tolerance; this mechanism might be associated with the development and progression of human malignancies. In the present study, we investigated the role of IDO in diethylnitrosamine (DEN)-induced hepatocarcinogenesis by using IDO-knockout (KO) mice. To induce hepatocellular carcinoma (HCC), hepatic adenoma, and preneoplastic hepatocellular lesions termed foci of cellular alteration (FCA), male IDO-wild-type (WT) and IDO-KO mice with a C57BL/6J background received a single intraperitoneal injection of DEN at 2 weeks of age. The mice were sacrificed to evaluate the development of FCA and hepatocellular neoplasms. HCC overexpressed IDO and L-kynurenine compared to surrounding normal tissue in the DEN-treated IDO-WT mice. The number and cell proliferative activity of FCAs, and the incidence and multiplicity of HCC were significantly greater in the IDO-WT than in the IDO-KO mice. The expression levels of the IDO protein, of L-kynurenine, and of IFN-γ, COX-2, TNF-α, and Foxp3 mRNA were also significantly increased in the DEN-induced hepatic tumors that developed in the IDO-WT mice. The mRNA expression levels of CD8, perforin and granzyme B were markedly increased in hepatic tumors developed in IDO-KO mice. Moreover, Foxp3-positive inflammatory cells had infiltrated into the livers of DEN-treated IDO-WT mice, whereas fewer cells had infiltrated into the livers of IDO-KO mice. Induction of IDO and elevation of L-kynurenine might play a critical role in both the early and late phase of liver carcinogenesis. Our findings suggest that inhibition of IDO might offer a promising strategy for the prevention of liver cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats.
- Author
-
Wada, Haruka, Shibata, Yuhei, Abe, Yurika, Otsuka, Ryo, Eguchi, Nanami, Kawamura, Yoshimi, Oka, Kaori, Baghdadi, Muhammad, Atsumi, Tatsuya, Miura, Kyoko, and Seino, Ken-ichiro
- Subjects
- *
MACROPHAGES , *CELL lines , *FLOW cytometry , *PHENOTYPES , *NUCLEAR magnetic resonance spectroscopy - Abstract
Naked mole rats (NMRs) have extraordinarily long lifespans and anti-tumorigenic capability. Recent studies of humans and mice have shown that many age-related diseases, including cancer, are strongly correlated with immunity, and macrophages play particularly important roles in immune regulation. Therefore, NMR macrophages may contribute to their unique phenotypes. However, studies of the roles of macrophages are limited by material restrictions and the lack of an established experimental strategy. In this study, we developed a flow cytometric strategy to identify NMR macrophages. The NMR macrophages were extractable using an off-the-shelf anti-CD11b antibody, M1/70, and forward/side scatter data obtained by flow cytometry. NMR macrophages proliferated in response to human/mouse recombinant M-CSF and engulfed Escherichia coli particles. Interestingly, the majority of NMR macrophages exhibited co-staining with an anti-NK1.1 antibody, PK136. NK1.1 antigen crosslinking with PK136 results in mouse NK cell stimulation; similarly, NMR macrophages proliferated in response to NK1.1 antibody treatment. Furthermore, we successfully established an NMR macrophage cell line, NPM1, by transduction of Simian virus 40 early region that proliferated indefinitely without cytokines and retained its phagocytotic capacity. The NPM1 would contribute to further studies on the immunity of NMRs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma.
- Author
-
Kaneda, Yuto, Kanemura, Nobuhiro, Nakamura, Nobuhiko, Ikoma, Yoshikazu, Yamaguchi, Kimihiro, Takada, Eri, Shibata, Yuhei, Lee, Shin, Fujita, Kei, Morishita, Tetsuji, Matsumoto, Takuro, Nakamura, Hiroshi, Kitagawa, Junichi, Kasahara, Senji, Hara, Takeshi, Tsurumi, Hisashi, and Shimizu, Masahito
- Subjects
- *
DIFFUSE large B-cell lymphomas , *OLDER patients , *NUTRITIONAL status , *PROGNOSIS , *PROPORTIONAL hazards models - Abstract
Predicting prognosis is crucial in older patients with diffuse large B-cell lymphoma (DLBCL). This study evaluated the prognostic impact of the controlling nutritional status (CONUT) score, a simple nutritional index, for older DLBCL patients (≥65 years of age) treated with R-CHOP-like regimens in a retrospective, cohort study including 203 patients. The CONUT score was an independent prognostic factor for overall survival (hazard ratio 1.11, 95% confidence interval (CI) 1.01-1.21, p = 0.032) in a multivariable Cox proportional hazards model. On receiver-operating characteristic analysis, the optimal cutoff value was 3. The CONUT score (≥3 or <3) effectively stratified older DLBCL patients, regardless of the International Prognostic Index (p = 0.71 for interaction). Further, the CONUT score independently affected initial dose intensity (odds ratio 0.84, 95% CI 0.73-0.95, p = 0.008), likely reflecting the patients' status at diagnosis and affecting dose adjustments. In conclusion, the CONUT score is associated with a poorer prognosis in older DLBCL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
- Author
-
Nakamura, Nobuhiko, Kanemura, Nobuhiro, Matsumoto, Takuro, Nakamura, Hiroshi, Ikoma, Yoshikazu, Shibata, Yuhei, Kitagawa, Junnichi, Kasahara, Senji, Yamada, Toshiki, Sawada, Michio, Kaneda, Yuto, Fukuno, Kenji, Takada, Eri, Goto, Hideko, Lee, Shin, Fujita, Kei, Morishita, Tetsuji, Hara, Takeshi, Tsurumi, Hisashi, and Shimizu, Masahito
- Subjects
- *
T-cell lymphoma , *OLDER people , *PROGNOSTIC models , *SURVIVAL rate , *PREDICTION models , *CHILD patients - Abstract
We compared the predictive ability of the International Prognostic Index (IPI), a frequently used prognostic model for peripheral T-cell lymphoma (PTCL), with that of a type-specific prognostic model, the Prognostic Index for PTCL-U (PIT). We retrospectively analyzed 113 patients diagnosed with PTCL. The median age was 67 years (range, 16–88 years), 75 patients (66%) were male, and the most common disease type was PTCL, not otherwise specified (69%). With a median follow-up of 6.8 years (interquartile range, 2.7–9.9 years), 5-year survival rates for the four groups in IPI were 85%, 62%, 49%, and 13%, respectively. Similarly, 5-year survival rates for the four groups in PIT were 83%, 64%, 49%, and 19%, respectively. The area under the receiving operating characteristic curve for predicting mortality from PIT (0.725) was not significantly different from that from the IPI (0.685, P = 0.134). Multivariable analysis showed that performance status ≥ 2 (P < 0.0001) and extranodal lesions ≥ 2 (P = 0.029) were significantly associated with lower overall survival. The present study found no significant difference in prognostic ability between the IPI and PIT for PTCL, and both models appear useful as predictive models. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Prognostic value of the combination of serum l -kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia.
- Author
-
Hara, Takeshi, Matsumoto, Takuro, Shibata, Yuhei, Nakamura, Nobuhiko, Nakamura, Hiroshi, Ninomiya, Soranobu, Kitagawa, Junichi, Nannya, Yasuhito, Shimizu, Masahito, Ito, Hiroyasu, Saito, Kuniaki, and Tsurumi, Hisashi
- Subjects
- *
INDOLEAMINE 2,3-dioxygenase , *KYNURENINE , *MESSENGER RNA , *GENE expression , *ACUTE myeloid leukemia , *POLYMERASE chain reaction , *GENETICS - Abstract
The article discusses the prognostic value of serum L-kynurenine (KYN) level combined with indoleamine 2,3-dioxygenase (IDO) mRNA expression in acute myeloid leukemia. Assessments performed include high-performance liquid chromatography, polymerase chain reaction for IDO mRNA expression analysis, and KYN pathway. The study concludes the useful combination of serum KYN concentration and IDO mRNA expression than either factor when considering the indications in AML patients.
- Published
- 2016
- Full Text
- View/download PDF
8. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
- Author
-
Nakamura, Nobuhiko, Hara, Takeshi, Shibata, Yuhei, Matsumoto, Takuro, Nakamura, Hiroshi, Ninomiya, Soranobu, Kito, Yusuke, Kitagawa, Junichi, Kanemura, Nobuhiro, Goto, Naoe, Shiraki, Makoto, Miyazaki, Tatsuhiko, Takeuchi, Tamotsu, Shimizu, Masahito, and Tsurumi, Hisashi
- Subjects
- *
ANTINEOPLASTIC agents , *B cell lymphoma , *DOXORUBICIN , *HUMAN reproduction , *MONOCLONAL antibodies , *PREDNISONE , *VINCRISTINE , *EQUIPMENT & supplies , *SARCOPENIA , *RETROSPECTIVE studies , *CYCLOPHOSPHAMIDE , *SKELETAL muscle , *PREDNISOLONE - Abstract
Sarcopenia reportedly predicts poor outcomes in elderly patients with diffuse large B-cell lymphoma (DLBCL). However, because previous studies only involved elderly patients, it is difficult to generalize these results to all patients with DLBCL. We retrospectively analyzed 207 patients with DLBCL who received the R-CHOP or R-THP-COP regimen between June 2004 and May 2014. Sarcopenia was measured by the analysis of CT images at the L3 level before treatment. The surface of muscular tissues was selected according to the CT Hounsfield unit. This value was normalized for stature in order to calculate the L3 skeletal muscle index (L3 SMI, cm(2)/m(2)). Median age at diagnosis in the 121 males and 86 females was 67 years (range, 19-86 years). The sex-specific cutoffs for the L3 SMI were determined by receiver operator curve (ROC) analysis. Sarcopenic patients were older than non-sarcopenic patients, with a median age of 70 and 65 years, respectively (p < 0.001). Other International Prognostic Index factors were not significantly different when comparing sarcopenic and non-sarcopenic patients. With a median follow-up of 50.4 months, the 3-year overall survival (OS) was 70 % in the sarcopenic group and 85 % in the non-sarcopenic group (p = 0.0260). In a subgroup analysis by gender, there was a significant difference in the OS when comparing sarcopenic and non-sarcopenic patients in males but not in females (p = 0.0003, p = 0.4440, respectively). Sarcopenia is an independent prognostic factor in male patients with DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
- Author
-
Nakamura, Nobuhiko, Kanemura, Nobuhiro, Lee, Shin, Fujita, Kei, Morishita, Tetsuji, Takada, Eri, Shibata, Yuhei, Kasahara, Senji, Goto, Hideko, Fukuno, Kenji, Hara, Takeshi, Yamada, Toshiki, Sawada, Michio, Tsurumi, Hisashi, and Shimizu, Masahito
- Subjects
- *
T-cell lymphoma , *NUTRITIONAL status , *PROPORTIONAL hazards models , *LYMPHOCYTE count , *OVERALL survival - Abstract
The controlling nutritional status (CONUT) score is a simplified nutritional index calculated from serum albumin, total cholesterol, and total lymphocyte count. This study evaluated the prognostic impact of the CONUT score on overall survival (OS) in patients with peripheral T-cell lymphoma (PTCL). A multicenter, retrospective cohort study including 99 patients with PTCL was conducted. The CONUT score was significantly higher in the non-survivor group (median 5, range 0-12) than in the survivor group (median 3, range 0-11; p = 0.026). The CONUT score was an independent prognostic factor in a multivariable Cox proportional hazards model (hazard ratio 1.119, 95% confidence interval 1.021-1.227, p = 0.017). No significant effect-modification by the International Prognostic Index (IPI) was observed, and the CONUT score affected the prognosis of PTCL regardless of the IPI (P for interaction = 0.208). In conclusion, the CONUT score is an independent prognostic factor for PTCL irrespective of IPI category. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
- Author
-
Nakamura, Nobuhiko, Kasahara, Senji, Kitagawa, Junichi, Nakamura, Hiroshi, Sawada, Michio, Fukuno, Kenji, Shibata, Yuhei, Kaneda, Yuto, Hara, Takeshi, Kanemura, Nobuhiro, Tsurumi, Hisashi, and Shimizu, Masahito
- Subjects
- *
MANTLE cell lymphoma , *FOLLICULAR lymphoma , *CYTARABINE , *RITUXIMAB , *FEBRILE neutropenia - Abstract
This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2–6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-year overall survival was 76.9%, and the 2-year progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematological toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy. Trial registration The UMIN Clinical Trials Registry, UMIN000009797. Registered 17 January 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000011103 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
- Author
-
Nakamura, Nobuhiko, Kanemura, Nobuhiro, Shibata, Yuhei, Matsumoto, Takuro, Mabuchi, Ryoko, Nakamura, Hiroshi, Kitagawa, Junichi, Goto, Naoe, Hara, Takeshi, Tsurumi, Hisashi, and Moriwaki, Hisataka
- Subjects
- *
IMMUNOGLOBULIN G , *MULTIPLE myeloma treatment , *COMBINATION drug therapy , *DEXAMETHASONE , *IMMUNOLOGICAL adjuvants , *PHARMACODYNAMICS , *PHYSIOLOGICAL effects of cytokines , *THERAPEUTICS ,SIDE effects of thalidomide - Abstract
The article presents a case study of a 76-year-old man with multiple myeloma (MM) who was admitted to the hospital. He had previously undergone treatment for MM with several combination drug therapies, which were discontinued due to adverse side effects. The article discusses the patient’s serum immunoglobulin G (IgG) level, combination drug treatment with lenalidomide and dexamethasone, and the induction of cytokine release syndrome by lenalidomide.
- Published
- 2014
- Full Text
- View/download PDF
12. Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas.
- Author
-
Takemura, Masao, Yamasuge, Wakana, Yamamoto, Yasuko, Saito, Kuniaki, Goto, Naoe, Adachi, Seiji, Saito, Koshiro, Yabe, Kuniaki, Takami, Tsuyoshi, Miyazaki, Tatsuhiko, Takeuchi, Tamotsu, Shiraki, Makoto, Shimizu, Masahito, Shibata, Yuhei, Nakamura, Nobuhiko, Hara, Takeshi, Tsurumi, Hisashi, and Serrero, Ginette
- Subjects
- *
PROGRANULIN , *BLOOD serum analysis , *LYMPHOMAS , *SURVIVAL analysis (Biometry) , *IMMUNOHISTOCHEMISTRY , *DIFFUSE large B-cell lymphomas , *PATIENTS , *PROGNOSIS - Abstract
Background GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML). Methods Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression. Results The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of ≤ 116 and > 116 ng/ml, had 5-y OS rates of 70% and 50%, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88. Conclusions High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia.
- Author
-
Mabuchi, Ryoko, Hara, Takeshi, Matsumoto, Takuro, Shibata, Yuhei, Nakamura, Nobuhiko, Nakamura, Hiroshi, Kitagawa, Junichi, Kanemura, Nobuhiro, Goto, Naoe, Shimizu, Masahito, Ito, Hiroyasu, Yamamoto, Yasuko, Saito, Kuniaki, Moriwaki, Hisataka, and Tsurumi, Hisashi
- Subjects
- *
KYNURENINE , *ACUTE myeloid leukemia , *TREATMENT effectiveness , *PROGNOSIS , *HIGH performance liquid chromatography , *PATIENTS - Abstract
The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 µM. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 µM (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
- Author
-
Fukuno, Kenji, Hara, Takeshi, Tsurumi, Hisashi, Shibata, Yuhei, Mabuchi, Ryoko, Nakamura, Nobuhiko, Kitagawa, Junichi, Shimizu, Masahito, Ito, Hiroyasu, Saito, Kuniaki, and Moriwaki, Hisataka
- Subjects
- *
INDOLEAMINE 2,3-dioxygenase , *ACUTE myeloid leukemia , *ACUTE myeloid leukemia diagnosis , *HUMAN cytogenetics , *REVERSE transcriptase polymerase chain reaction , *MESSENGER RNA , *TRYPTOPHAN , *PROGNOSIS - Abstract
The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively ( p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively ( p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. P1-272Adult rhabdomyosarcoma with bleeding tendency as an initial clinical manifestation.
- Author
-
Goto, Hideko, Kaneda, Yuto, Yamaguchi, Kimihiro, Shibata, Yuhei, Watanabe, Naoki, Goto, Naoe, Kasahara, Senji, Katsumura, Naoki, Tanaka, Takuji, and Takahashi, Takeshi
- Subjects
- *
RHABDOMYOSARCOMA , *MUSCLE tumors , *SARCOMA - Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.